Kopran Limited (KOPRAN) unveils its FY 2025-26 corporate presentation, highlighting significant financial and operational milestones.
Glenmark Pharmaceuticals Limited announces new development candidate ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumors.
Dishman Carbogen Amcis Limited (DCAL) reports a 18.9% revenue increase in Q4 FY26, driven by growth in CDMO and Marketable Molecules segments.
Eris Lifesciences Limited (ERIS) reports Q4 and FY2026 results with notable growth in the insulin segment and a 37% EBITDA margin.
Anthem Biosciences Limited (NSE: ANTHEM) announced its Q4 FY26 results with a 26% YoY revenue growth and a 129.8% surge in PAT.
Mankind Pharma Limited (MANKIND) reported a 11.8% revenue increase and an adjusted EBITDA margin of 27.1% in Q4 FY26.
Viyash Scientific Limited (VIYASH) reports record Q4 FY26 results with EBITDA surpassing Rs. 200 Cr and PAT up by 306%.
Zota Health Care Limited (ZOTA) announces brand expansion with Mr. Akshay Kumar as brand ambassador for UGO Generic, enhancing national presence.
Nephrocare Health Services Limited (NEPHROPLUS) reports Q4 FY26 revenue up 21.2% to ₹265.6 crore, adjusted EBITDA rises 2.6% to ₹55.4 crore.
ZIM Laboratories Limited (ZIMLAB) secures MA for Dabigatran Etexilate in Italy and Europe, boosting global commercial opportunities.